INTRODUCTION {#S1}
============

Some studies suggest a graft-versus-myeloma effect after allogeneic haematopoietic stem cell transplantation (HSCT) for multiple myeloma (MM)([@R1]--[@R4]). For example, donor lymphocyte infusions (DLI) have induced remission in patients with recurrent MM after HSCT. In recipients of allogeneic HSCT after traditional myeloablative conditioning, the graft-versus-myeloma effect is suggested by the fact that chronic GVHD correlates with complete remission([@R5]). However, other studies report no correlation ([@R6]). Despite the beneficial graft-versus-myeloma effect, the high treatment-related mortality (TRM), mainly related to graft-versus-host disease (GVHD), has made myeloablative HSCT unattractive compared with autologous transplants or new drugs ([@R7]--[@R9]).

Recently, allogeneic transplantations have been used earlier in the course of MM and with reduced conditioning intensity, in an attempt to reduce TRM after HSCT([@R10]). A promising approach is the combination of high-dose chemotherapy and autologous transplant, followed by reduced-intensity HSCT([@R11]). This approach relies on a maximal disease control strategy with autologous transplantation followed by lower-intensity conditioning allogeneic HSCT to achieve an immune-mediated graft-versus-myeloma effect([@R6], [@R11]--[@R14]).

Two randomised studies in high risk MM patients indicated that autologous followed by allogeneic HSCT had similar outcomes compared with tandem autologous transplantation([@R13], [@R14]). Studies not limited to high risk MM patients with autologous followed by allogeneic approach, compared with tandem autologous transplantation, have shown discordant results with an earlier Italian study showing a survival advantage, whereas the recently reported Bone Marrow Transplant Clinical Trials Network 0102 study showed no benefit to allogeneic transplantation([@R12], [@R15]).

With reduction in conditioning intensity, any beneficial effect of allogeneic HSCT is likely to be derived from an immune-mediated graft-versus-MM effect, but the relative impact of this effect has been difficult to characterize. A retrospective study by Crawley et al. showed that chronic GVHD was associated with superior survival in patients treated with reduced-intensity allogeneic transplantation ([@R16]). Another prospective study suggested no correlation between chronic GVHD and response in patients undergoing autologous followed by allogeneic HSCT for MM([@R6]). Interestingly, the study by Crawley et al. did not specifically address the upfront planned autologous followed by allogeneic HSCT approach([@R16]).

We analyzed the impact of acute and chronic GVHD on outcomes in myeloma patients undergoing allogeneic HSCT following reduced-intensity conditioning, both in the planned autologous followed by allogeneic (auto-allo) and the single upfront allogeneic HSCT (not preceded by autotransplant) settings.

PATIENTS AND METHODS {#S2}
====================

Patient Selection {#S3}
-----------------

Recipients of HLA-identical sibling bone marrow and/or peripheral blood stem cell allogeneic transplants for MM within 18 months of diagnosis, between 1997 and 2005 and reported to the CIBMTR (Center for International Blood and Marrow Transplant Research) were identified. Reduced-intensity regimens were defined and classified as non-myeloablative conditioning (NMA) or reduced-intensity conditioning (RIC) based on standard definitions([@R17]). The patients were grouped into those receiving a single allogeneic HSCT (allo only) and those receiving a planned autologous followed by allogeneic HSCT (auto-allo). Patients who received an autologous HSCT followed by an unplanned allogeneic HSCT at progression (n=16) were excluded from the study.

Data Source {#S4}
-----------

The CIBMTR is a research organisation of more than 450 transplant centers worldwide, that contribute detailed data on consecutive transplants. Patients are followed longitudinally, with yearly follow-up. Computerised checks for errors, physician reviews of submitted data and on-site audits of participating centers ensure data quality.

Outcomes {#S5}
--------

Overall survival was defined as the time from date of transplant to date of death, with survivors censored at the time of last contact. Transplant-related mortality (TRM) was defined as death occurring in the absence of relapse/progressive disease and summarized by the cumulative incidence estimate with relapse as the competing risk.

Relapse/progression was defined as the time to first evidence of laboratory recurrence or progression of myeloma according to the standard EBMT/IBMTR criteria([@R18]) and summarized by the cumulative incidence estimate with TRM as the competing risk. Event-free survival (EFS) was defined as survival without progressive disease or relapse from complete remission (CR). Progressive disease, relapse from CR and death in remission were considered events. Probabilities of survival and EFS were calculated using the Kaplan--Meier estimator and compared using the log-rank test. The incidence and stage of acute GVHD (aGVHD) were measured by standard criteria([@R19]). The incidence of chronic GVHD (cGVHD) was measured according to the standard criteria([@R20]).

Statistical Analysis {#S6}
--------------------

Multivariate analyses were performed using Cox proportional hazards models. A stepwise model-building approach was used to identify the significant risk factors associated with outcomes of TRM, relapse, EFS and overall survival. The variables considered in the model-building procedures were as follows: age at transplant (\<50 years vs. ≥50 years), gender (male vs. female), Karnofsky performance score (\<90 vs. ≥90 vs. unknown), Durie-Salmon stage at diagnosis (I/II vs. III), disease status and sensitivity of MM to chemotherapy prior to transplant (sensitive vs. not sensitive vs. others), prior lines of chemotherapy (≤1 line vs. 2 lines vs. \>2 lines), type of transplant (allo only vs. auto+allo), donor-recipient sex match (male-to-male vs. male-to-female vs. female-to-male, vs. female-to-female), conditioning (NMA vs. RIC), year of transplant (≤ 2001 vs. \>2001), acute and chronic GVHD. At the time of transplantation, it is unknown who will and who will not develop GVHD. Therefore GVHD was treated as a time-dependent covariate. Since acute and chronic GVHD effects are the main interests of this study, they were included in each step of model building. Factors that were significant at a 5% level were kept in the final model. The potential interactions between main effects and all significant risk factors were tested. The relative risks of significant covariates based on final models were reported. In addition to considering GVHD as a time-dependent covariate, we used a landmark analysis method to compute outcomes stratified by patients who developed acute GVHD within 100 days. Patients surviving longer than 100 days were included in acute GVHD landmark analysis. A similar landmark study for those who developed chronic GVHD within 1 year of transplant was also performed. Landmark analyses results are presented in figures.

RESULTS {#S7}
=======

Pre-transplant Characteristics {#S8}
------------------------------

[Table 1](#T1){ref-type="table"} summarizes patient, disease and transplant-related variables of interest. Fifty-five percent of the patients had IgG MM and 63% had Salmon-Durie stage III. Seventy-two percent of the patients were in complete or partial remission at the time of transplantation. Fifty-six percent of the patients received NMA. The most common immunosuppressive protocols were cyclosporine combined with mycophenolate mofetil, or cyclosporine combined with methotrexate.

Outcomes {#S9}
--------

[Table 2](#T2){ref-type="table"} summarizes the univariate outcomes after allogeneic HSCT. [Table 3](#T3){ref-type="table"} summarizes the results of the multivariate analysis.

Graft-versus-host disease {#S10}
-------------------------

The cumulative incidence of acute GVHD grades I--IV at 100 days was 42% (95% CI, 35--49%). Overall acute GVHD grades II--IV was observed in 53 patients (30%) ([Table 2](#T2){ref-type="table"}). Chronic GVHD at one year was 45% (95% CI, 37--52%). At five years, it was 59% (95% CI, 49--69%) with 70% of cGVHD was extensive.

Transplant-related mortality {#S11}
----------------------------

At one year, TRM was 15% (95% CI, 10--20%), and at five years it was 25% (95% CI, 17--34%). In multivariate analysis, acute GVHD was associated with an increased risk of TRM ([Table 3](#T3){ref-type="table"}, RR 2.42, p=0.016). Chronic GVHD, whether limited or extensive, had no significant impact on TRM. [Figures 1a and 1b](#F1){ref-type="fig"} represent the landmark analyses for TRM in those developing aGVHD by day 100 vs. those who did not, and those developing cGVHD within 1 year vs. those who did not.

Relapse {#S12}
-------

Cumulative incidence of relapse at one year was 22% (95%CI, 16--28%). At five years, the incidence of relapse was 52% (95%CI, 41--63%). Acute GVHD had no statistically significant effect on the risk of relapse. Chronic GVHD overall was associated with a reduced risk of relapse in the multivariate analysis, but the beneficial effect was confined to those with limited cGVHD (RR=0.35, p=0.035) but was not statistically significant in those with extensive chronic GVHD (RR=0.58, p=0.14) ([Table 3](#T3){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} represents the additional landmark analysis for relapse in those who developed any cGVHD within 1 year of HSCT vs. those who did not.

The cumulative incidence of relapse at 1 year was 32% (95% CI 21--43%) in the allo only group vs.15% (95% CI 8--22%) in the auto-allo group. The auto-allo group had a significantly lower risk of relapse in multivariate analysis, compared to the allo-only group ([Table 3](#T3){ref-type="table"}, RR 0.59; p=0.043).

Event-free survival {#S13}
-------------------

At one year, EFS was 64% (95% CI, 57--71%), and at five years, it was 22% (95% CI, 13--34%). In the multivariate analysis, aGVHD and cGVHD overall did not impact EFS ([Table 3](#T3){ref-type="table"}). However, limited cGVHD was associated with superior EFS (RR for relapse/death =0.40, p=0.027), while extensive cGVHD had no statistically significant impact on EFS. [Figure 3](#F3){ref-type="fig"} depicts a landmark analysis of EFS in those developing any cGVHD within one year of HSCT vs. those who did not. At one year, EFS was 48% (95% CI 36--60%) in the allo only group, compared to 74% (95% CI 66--83%) in the auto-allo group. At five years, EFS was 17% (95% CI 7--29%) and 24% (95% CI 7--48%) in the two groups, respectively. In the multivariate analysis, the auto-allo group had superior EFS ([Table 3](#T3){ref-type="table"}, RR=0.57, p=0.008).

Overall survival {#S14}
----------------

At one year, survival was 75% (95%CI, 69--82%), and at five years it was 38% (95%CI, 26--50%). Acute GVHD was not associated with survival in the allo-only cohort ([Table 3](#T3){ref-type="table"}, RR of death =0·90, p=0·75). In the Auto-allo cohort, acute GVHD was associated with a higher risk of death (RR=3·52, p=0·001). Chronic GVHD on the other hand, had no significant impact on survival.

Causes of Death {#S15}
---------------

The most common cause of death was relapsed or progressive MM in 33% patients, followed by infections and organ failure.

DISCUSSION {#S16}
==========

This aim of this analysis was to define the impact of GVHD on outcomes after allogeneic HSCT for MM. Acute GVHD is the major underlying cause of morbidity and TRM following allogeneic HSCT in patients with MM([@R6]). High TRM, mainly related to GVHD, made myeloablative HSCT unacceptable for most patients with MM([@R8], [@R21]). In addition, only a limited number of myeloma patients are candidates for myeloablative allogeneic HSCT, because of age, non-availability of HLA-matched donors and pre-transplant co-morbidities. The advent of reduced-intensity conditioning has led to increased numbers of patients becoming eligible for HSCT as well as hope of reduced risk of TRM. However, the success of this modality is dependent on immune mediated graft-versus-myeloma effect since anti-neoplastic effect derived from the conditioning regimen is modest. We attempted to evaluate the relative impact of aGVHD and cGVHD on TRM, relapse and survival endpoints.

In the present study, patients receiving allogeneic HSCT for MM had a significant late risk of relapse (52% at 5 years). A striking finding is the high number of late relapses, especially among the patients who did not develop chronic GVHD ([Fig. 2](#F2){ref-type="fig"}). This is especially striking when we do a landmark analysis, because relapses occurring during the first year are not included in the figure. The continuous increase in relapses is not specific for this study, but is often seen in patients undergoing HSCT for myeloma ([@R6], [@R8], [@R10], [@R22]).

There were significant risks of acute and chronic GVHD consistent with previous observations([@R22]). The probability of grade III--IV acute GVHD after RIC/NMA was 15%. In this group, mortality from GVHD is typically high([@R23]). Similar to previous studies in leukemia patients, acute GVHD was associated with a significant increase in risk of TRM ([Table 3](#T3){ref-type="table"}) whereas chronic GVHD overall was not associated with increased TRM ([Table 3](#T3){ref-type="table"}, [Fig. 1b](#F1){ref-type="fig"}). The negative impact of aGVHD on survival was marked in the planned Auto-allo cohort.

Several small studies have suggested a graft-versus-MM effect in patients receiving allogeneic HSCT after myeloablative conditioning ([@R1]--[@R5], [@R16]). Our study demonstrates that in the setting of RIC or NMA, chronic GVHD especially limited cGVHD is associated with beneficial impact with a decreased risk of myeloma relapse and superior EFS ([Table 3](#T3){ref-type="table"}). Acute GVHD on the other hand had no impact on relapse. This is in keeping with most studies of the graft-versus-leukemia effect, showing that chronic GVHD has the strongest association with decreased relapse, whereas the effect of acute GVHD on relapse was manifest in some, but not all studies ([@R24]--[@R27]).

A reduced relapse risk was significantly associated with limited but not extensive chronic GVHD. This is in contrast to a study in patients with acute leukemia, showing that there was no difference in relapse in patients with limited or extensive chronic GVHD ([@R25]). There may be several reasons why we didn't find a reduced relapse risk in patients with extensive chronic GVHD. First, this is a multicenter study and there may be difficulties associated with the distinction between limited and extensive disease. Furthermore, there is a limited number of patients included and there may not have been sufficient patient numbers to find a significant effect in patients with extensive chronic GVHD. We may also speculate that patients with extensive chronic GVHD are treated with more heavy immunosuppressive therapy that may abrogate the graft-versus-myeloma effect to a larger extent than the milder immunosuppression used in patients with limited disease.

In the comparison between allo-only and auto-allo cohorts, there were significantly lower early relapses and superior EFS in the auto-allo group, compared with the allo-only group ([Table 3](#T3){ref-type="table"}). The reason for the reduction in early relapse and improved EFS in the auto-allo group may be due to a selection bias favoring more high risk patients proceeding to an initial allogeneic transplant without a preceding autograft (supplemental data not shown). The allo-only group had markers of worse prognosis at baseline, including a higher proportion of patients with light chain and non-secretory disease (p\<0.001), those with three or more lines of pretransplant chemotherapy (p=0.01), and fewer patients with chemotherapy sensitive disease compared with the auto-allo group. The allo-only group also received RIC including Melphalan (p\<0.001) based conditioning more often, suggesting a higher intensity of conditioning within the reduced-intensity category. This is also consistent with the notion that some of these patients were selected since they had more advanced disease and were considered for more "intensive conditioning" within the RIC spectrum.

There was no increase in TRM associated with chronic GVHD ([Table 3](#T3){ref-type="table"}). This suggests that any graft-versus-MM effect induced by chronic GVHD not only decreased the probability of relapse, but had no adverse effect on survival. A study by Crawley et al showed that chronic GVHD was associated with improved EFS([@R16]). EFS was also not significantly impacted by acute GVHD despite its association with higher risk of TRM. The reason for this mitigating effect may be an association between acute and chronic GVHD (p-value = 0.03). The increased mortality risk associated with aGVHD was statistically significant in the Auto-allo group but not in the allo-only group. The reason for this may also be due to the selection of higher risk patients in the allo-only group.

Chronic GVHD had no impact on overall survival despite lower relapse and unchanged TRM. Also the impact of chronic GVHD on quality of life and co-morbidities cannot be measured in this analysis. This also suggests that currently the role of allotransplantation in MM remains limited by lack of adequate long term disease control, a persistent risk of relapse and death from recurrent myeloma. These findings are consistent with emerging data from randomized studies such as the BMTCTN 0102 study([@R15]).

In conclusion, our analysis demonstrates a beneficial effect on relapse risk reduction associated with limited chronic GVHD without an increased risk of TRM. These findings have implications for clinical practice and future trials in allogeneic HSCT for MM. In this study, 59% of the patients with acute GVHD developed chronic GVHD and 30% of them had limited chronic GVHD. In clinical practice, this figure may be increased by early discontinuation of immunosuppression in the absence of GVHD([@R28]). However, early immunosuppression should be the best available to prevent acute GVHD, since it was associated with an increased risk of TRM and decreased survival. These findings could also prompt wider use of donor lymphocyte infusions to induce graft-versus-myeloma effect in selected settings. Despite the promise of a graft-versus-myeloma effect, the major current shortcoming of allogeneic transplantation in MM is the ongoing risk of relapse. These are best addressed in prospective trials incorporating more novel conditioning and maintenance strategies.
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###### 

Figure. 1a. Acute GVHD and transplant-related mortality (TRM) in patients with (grades I--IV) and without any acute GVHD by day 100 (Landmark analysis)

Figure. 1b. Chronic GVHD and transplant-related mortality (TRM) in patients with and without chronic GVHD within one year (Landmark analysis)
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![Relapse in patients with and without chronic GVHD within one year (Landmark analysis)](nihms316760f2){#F2}

![Event-free survival (EFS) in patients with and without chronic GVHD within one year (Landmark analysis)](nihms316760f3){#F3}

###### 

Characteristics of patients

  Variables                                       N (%)
  ----------------------------------------------- ---------------
  **[Patient-related]{.ul}**                      
  Number of patients                              177
  Number of centers                               65
  Age, median (range), years                      51 (24 -- 69)
  Male sex                                        102 (58)
  Karnofsky score at transplant ≥ 90%             121 (68)
  **[Disease-related]{.ul}**                      
  Immunochemical subtype of MM                    
   IgG                                            97 (55)
   IgA                                            23 (13)
   IgD                                            4 (2)
   Light chain                                    39 (22)
   Non secretory/Other                            14 (8)
  Salmon-Durie stage at diagnosis                 
   I                                              8 (4)
   II                                             39 (22)
   III                                            111 (63)
   Missing                                        19 (11)
  Albumin at diagnosis \<3.5 g/dL                 47 (26)
  Prior lines of chemotherapy                     
   1                                              79 (45)
   2                                              43 (24)
   ≥3                                             25 (14)
   Missing/Unknown                                30 (17)
  Disease status prior to transplant              
   Complete remission/Partial remission           127 (72)
   Minimal response                               10 (6)
   No response/Stable disease                     16 (9)
   Progression                                    2 (1)
   Missing                                        22 (12)
  Bortezomib pre transplant                       8 (5)
  Thalidomide pre transplant                      44 (25)
  **[Transplant-related]{.ul}**                   
  Conditioning regimen                            
  ***Reduced-intensity conditioning***            
   TBI based                                      2 (1)
   Melphalan≤150 mg/m\^2                          37 (21)
   Busulfan≤9 mg/kg                               13 (7)
   Cyclophosphamide                               27 (15)
  ***Non-myeloablative conditioning***            
   TBI=200cGY                                     54 (31)
   Fludarabine+TBI=200cGY                         26 (15)
   Other                                          18 (10)
  Donor age, median (range), years                46 (16 -- 73)
  Female donor/male recipient                     52 (29)
  Donor-recipient CMV serostatus, −/−             43 (24)
  Peripheral blood stem cells                     173 (98)
  GVHD prophylaxis                                
   CSA based ± MTX                                52 (29)
   FK506 based ± MTX                              23 (13)
   CSA + MMF                                      86 (49)
   FK506 + MMF                                    2 (1)
   Campath ± other                                2 (1)
   Other/Unknown                                  12 (7)
  Year of transplant                              
   1997--1999                                     6 (4)
   2000                                           17 (9)
   2001                                           28 (16)
   2002                                           24 (14)
   2003                                           18 (10)
   2004                                           44 (25)
   2005                                           40 (22)
  Median (range) follow-up of survivors, months   29 (3 -- 98)

[Abbreviations]{.ul}: TBI = total body irradiation; CsA = cyclosporine; MTX = methotrexate; FK506 = tacrolimus; MMF = mycophenolate.

###### 

Univariate outcomes of GVHD, TRM, EFS and OS after Allogeneic HSCT

  Outcomes                                  N Eval   Probability (95% CI)
  ----------------------------------------- -------- ----------------------
  Maximum overall acute GVHD grade, N (%)   177      
   0                                                 92 (52)
   I                                                 32 (18)
   II                                                27 (15)
   III                                               23 (13)
   IV                                                3 (2)
  Acute GVHD (grade I -- IV) @ 100 days     177      42 (35 -- 49)
  Chronic GVHD                              176      
   @ 1 yr                                            45 (37 -- 52)
   @ 5 yrs                                           59 (49 -- 69)
  Extensive cGVHD                                    59 (70%)
  Any GVHD @ 5 yrs                          177      72 (65 -- 79)
  100-day mortality                         177      8 (5 -- 13)
  Treatment-related mortality               177      
   @ 1 yr                                            15 (10 -- 20)
   @ 5 yrs                                           25 (17 -- 34)
  Relapse/progression                       177      
   @ 1 yr                                            22 (16 -- 28)
   @ 5 yrs                                           52 (41 -- 63)
  Event-free survival                       177      
   @ 1 yr                                            64 (57 -- 71)
   @ 5 yrs                                           22 (13 -- 34)
  Overall survival                          177      
   @ 1 yr                                            75 (69 -- 82)
   @ 5 yrs                                           38 (26 -- 50)

###### 

Multivariate analysis

  Outcome                                                   Relative Risk (95% CI)                P-value
  --------------------------------------------------------- ------------------------------------- ---------
  **[TRM]{.ul}**^b^                                                                               
  Acute GVHD                                                                                      
   No                                                       1.00[a](#TFN2){ref-type="table-fn"}   
   Yes                                                      2.42 (1.18 -- 4.96)                   0.016
  **[Relapse]{.ul}**^c^                                                                           
  Type of transplant                                                                              
   First allogeneic                                         1.00[a](#TFN2){ref-type="table-fn"}   
   Planned autologous+allogeneic                            0.59 (0.36 -- 0.98)                   0.043
  Chronic GVHD                                                                                    
   No                                                       1.00[a](#TFN2){ref-type="table-fn"}   
   Limited                                                  0.35 (0.13 -- 0.93)                   0.035
   Extensive                                                0.58 (0.29 -- 1.19)                   0.14
  **[Event-free survival (RR of relapse/death)]{.ul}**^d^                                         
  Type of transplant                                                                              
   First allogeneic                                         1.00[a](#TFN2){ref-type="table-fn"}   
   Planned autologous+allogeneic                            0.57 (0.38 -- 0.86)                   0.008
  Chronic GVHD                                                                                    
   No                                                       1.00[a](#TFN2){ref-type="table-fn"}   
   Limited                                                  0.40 (0.19 -- 0.90)                   0.027
   Extensive                                                0.81 (0.47 -- 1.41)                   0.56
  **[Overall survival (RR of death)]{.ul}**^e^                                                    
  Acute GVHD                                                                                      
   First allogeneic                                                                               
    No                                                      1.00[a](#TFN2){ref-type="table-fn"}   
    Yes                                                     0.90 (0.48 -- 1.70)                   0.75
   Planned autologous+allogeneic                                                                  
    No                                                      1.00[a](#TFN2){ref-type="table-fn"}   
    Yes                                                     3.52 (1.67 -- 7.45)                   0.001

Reference group

GVHD impact (yes vs. no) on outcomes where not significant summarized below:

^b^Limited chronic GVHDRR=0.65 (0.17--2.47)p=0.53^b^Extensive chronic GVHDRR=1.50 (0.61--3.70)p=0.37^c^Acute GVHDRR=0.79 (0.47--1.36)p=0.40^d^Acute GVHDRR=1.10 (0.72--1.68)p=0.66^e^Limited cGVHDRR=0.45 (0.18--1.13)p=0.09^e^Extensive cGVHDRR=1.18 (0.66--2.10)p=0.59^e^Test interaction: p(~first\ allogeneic=planned\ autologous+allogeneic~) = 0.005
